<!doctype html>
<html lang="en"><head>
<meta charset="utf-8"/><meta name="viewport" content="width=device-width,initial-scale=1"/>
<link rel="stylesheet" href="/newsletter/style.css"/>
<title>Hologic&#x27;s Breast Health Rebound in Motion: How to Play the Stock Now? — Newsletter</title>
</head><body>
<div class="container">
  <div class="header">
    <h1 style="margin:0;font-size:28px">Newsletter</h1>
    <a class="btn" href="/newsletter/">Home</a>
  </div>
  <div class="card">
    <h2 style="margin-top:0">Hologic&#x27;s Breast Health Rebound in Motion: How to Play the Stock Now?</h2>
    <div class="badge">2025-09-15T13:00:00+00:00</div>
    <ul>
      <li>DHR, which fell 7.3% and 10.6%, respectively.</li>
<li>In the last six months, shares of HOLX have risen 4.2% against the industry’s 7% decline and the Zacks Medical sector’s 6.3% fall.</li>
<li>Based on planned mitigation efforts, the company anticipates direct tariff costs to be nearly $10 million-$12 million per quarter from fiscal 2026, down from the initial $20 million-$25 million forecast.</li>
<li>With only about 12% market penetration, Hologic expects Biotheranostics to emerge as a key growth platform in the future.</li>
<li>Hologic’s latest innovation, the Genius AI Detection PRO, builds on its flagship Genius AI Detection 2.0 Solution, featuring advanced workflows, enhanced diagnostic accuracy and up to 24% reduction in radiologists’ overa</li>
<li>To derisk itself from future geopolitical turmoil, Hologic had lowered its China revenue forecast by $20 million, now expecting only $50 million.</li>
<li>In addition, the team rolled out a new strategy to upgrade older end-of-life gantries, which is set to gain more traction in the fourth quarter and into 2026.</li>
    </ul>
    <p>
      <a class="btn" href="https://twitter.com/intent/tweet?text=Hologic&amp;#x27;s Breast Health Rebound in Motion: How to Play the Stock Now?\n• DHR, which fell 7.3% and 10.6%, respectively.\n• In the last six months, shares of HOLX have risen 4.2% against the industry’s 7% decline and the Zacks Medical sector’s 6.3% fall.\n• Based on planned mitigation efforts, the company anticipates direct tariff costs to be nearly $10 million-$12 million per quarter from fiscal 2026, down from the initial $20 million-$25 million forecast.\n• With only about 12% market penetration, Hologic expects Biotheranostics to emerge as a key growth platform in the future.\n• Hologic’s latest innovation, the Genius AI Detection PRO, builds on its flagship Genius AI Detection 2.0 Solution, featuring advanced workflows, enhanced diagnostic accuracy and up to 24% reduction in radiologists’ overa\n• To derisk itself from future geopolitical turmoil, Hologic had lowered its China revenue forecast by $20 million, now expecting only $50 million.\n• In addition, the team rolled out a new strategy to upgrade older end-of-life gantries, which is set to gain more traction in the fourth quarter and into 2026." target="_blank" rel="noopener">Tweet bullets</a>
      &nbsp;&nbsp;
      <a href="https://finance.yahoo.com/news/hologics-breast-health-rebound-motion-130000470.html" target="_blank" rel="noopener nofollow">finance.yahoo.com</a>
    </p>
  </div>
  <div class="footer">Built from digest_5bullets.md</div>
</div>
</body></html>